Compared to Estimates, Glaukos (GKOS) Q3 Earnings: A Look at Key Metrics
For the quarter ended September 2026, Glaukos (GKOS) reported revenue of $211.03 million, up 58% over the same period last year. EPS came in at $0.47, compared to -$0.16 in the year-ago quarter.
The reported revenue represents a surprise of +24.99% over the Zacks Consensus Estimate of $168.84 million. With the consensus EPS estimate being -$0.12, the EPS surprise was +491.67%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Glaukos performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:- Revenues by geography- United States: $174.85 million versus $132.79 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +72.4% change.
- Revenues by product category- United States- Glaucoma: $118.64 million versus the four-analyst average estimate of $112.85 million. The reported number represents a year-over-year change of +46.8%.
- Revenues by product category- International- Corneal Health: $2.83 million versus $2.7 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +7% change.
- Revenues by geography- International: $36.18 million versus $35.5 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +12.8% change.
- Revenues by product category- International- Glaucoma: $33.36 million compared to the $32.8 million average estimate based on four analysts. The reported number represents a change of +13.5% year over year.
- Revenues by product category- United States- Corneal Health: $56.21 million versus the four-analyst average estimate of $19.93 million. The reported number represents a year-over-year change of +172.3%.
- Net Sales- Corneal Health: $59.04 million versus the five-analyst average estimate of $23.1 million. The reported number represents a year-over-year change of +153.4%.
- Net Sales- Glaucoma: $151.99 million versus $146.32 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +37.9% change.
View all Key Company Metrics for Glaukos here>>>
Shares of Glaukos have returned +14.3% over the past month versus the Zacks S&P 500 composite's -0.2% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This innovative software-as-a-service firm upped its user base +22% year over year. That rate is increasing and margins are expanding as AI efficiencies take effect. Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.
Free: See Our Top Stock And 4 Runners UpGlaukos Corporation (GKOS) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
